- Home
- / 4D Molecular Therapeutics
4D Molecular Therapeutics
Stock Price
$8.2
2024-10-29
Market Capitalization
$426.2 M
2024-10-29
Revenue
$85.2 M
FY, 2025
4D Molecular Therapeutics Summary
Company Summary
- Overview
- 4D Molecular Therapeutics is a biotechnology company focused on the creation of gene therapy products to cure genetic diseases. Its Therapeutic Vector Evolution platform enables to create adeno-associated virus (AAV) gene therapy vectors, which deliver genes to any diseased tissue or organ in the body.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Emeryville, CA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Melissa Kotterman, Vice President, Head of Discovery & Engineering, Co-Founder
Katy Barglow, Vice President, Process and Analytical Development
Joseph Leonetti, Associate Director, CMC Project Management
Operating MetricsView all
Lead Optimization Stage Products
3
Q2, 2019
IND-Enabling Stage Products
3
Q3, 2020
Phase I Trials Products
3
Q3, 2020
LocationsView all
1 location detected
Emeryville, CA HQ
United States
5858 Horton St #455
4D Molecular Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $3.0M
- Net income (Q1, 2026)
- ($68.8M)
- Cash (Q1, 2026)
- $72.5M
- EBIT (Q1, 2026)
- ($73.6M)
- Enterprise value
- $374.2M